Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 29, 2006
Event: Termination of a Material Definitive Agreement.
On May 29, 2006, DaVita Inc. notified Gambro Renal Products Inc. of its intent to terminate the "Alliance and Product Supply Agreement" dated October 5, 2005. This agreement, entered into during DaVita's acquisition of Gambro Healthcare, Inc., obligated DaVita to purchase a significant majority of its hemodialysis products, supplies, and equipment from Gambro Renal Products at fixed prices.
Key Financial Metrics
This filing is a current report regarding a contractual event and does not contain specific financial statements, revenue figures, profit margins, cash flow data, or debt levels for the reporting period.
Financial Impact Assessment:
- Material Adverse Impact: The Company does not expect the termination to have a material adverse impact on its overall financial condition.
- Termination Penalties: The Company does not believe it will incur any material early termination penalties.
Material Changes and Event Details
Reason for Termination: The termination notice claims a material breach by Gambro Renal Products in the performance of its obligations under the Supply Agreement.
Effective Date: Termination will be effective 90 days after notice (August 27, 2006), provided that:
- Gambro Renal Products has not cured the breach within the 90-day period; or
- If a cure is not possible within 90 days, Gambro Renal Products has failed to commence or diligently continue steps agreed upon to result in a cure or prevent similar subsequent breaches.
Relationship Status: Gambro Renal Products and its parent, Gambro AB, do not have any other material relationship with DaVita or its affiliates.
Outlook, Risks, and Contingencies
Management Commentary: Management asserts that the termination is due to a material breach by the supplier and anticipates no significant financial disruption or penalties.
Risks and Uncertainties: The filing contains forward-looking statements regarding the lack of material adverse impact and penalties. These statements involve substantial known and unknown risks and uncertainties that could cause actual results to differ materially from expectations. Specific risks are referenced in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2006.
Contingencies: The finalization of the termination is contingent on Gambro Renal Products' ability to cure the alleged breach within the 90-day window.
Key Facts for Investor Verification
- Verify the specific nature of the "material breach" alleged by DaVita against Gambro Renal Products.
- Monitor whether Gambro Renal Products cures the breach or initiates cure steps before the August 27, 2006 effective date.
- Review the Company's Form 10-Q for the quarter ended March 31, 2006, for detailed risk factors related to this event.
- Confirm the availability of alternative suppliers for hemodialysis products should the termination become effective.